ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.

William D Tap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.